Jinan Zhuocheng Bio-Tech Co., Ltd.

Recently, the 2026 edition of China’s National Essential Medicines List was officially released, with a total of 20 products from Xinhua Pharmaceutical newly included in the list. The newly selected products cover a broad range of therapeutic areas, including anti-infectives, antivirals, cardiovascular and cerebrovascular diseases, metabolic disorders, digestive diseases, and neurological conditions, further strengthening the company’s product portfolio in support of China’s national essential medicines system.

China’s National Essential Medicines List is an important policy instrument for meeting basic healthcare needs. Medicines included in the list are given policy priority in procurement, supply, and clinical use, particularly at primary healthcare institutions, with the aim of improving access to safe, effective, and cost-efficient medicines for patients.

The 20 newly included products are:

• Rabeprazole Sodium Enteric-coated Tablets
• Sevelamer Carbonate Tablets
• Mecobalamin Tablets
• Empagliflozin Tablets
• Febuxostat Tablets
• Irbesartan Tablets
• Ezetimibe Tablets
• Cefixime Capsules
• Azithromycin for Oral Suspension
• Clindamycin Phosphate Injection
• Oseltamivir Phosphate for Oral Suspension
• Entacapone Tablets
• Nimodipine Injection
• Dobutamine Hydrochloride Injection
• Aminophylline Injection
• Esomeprazole Sodium for Injection
• Ursodeoxycholic Acid Capsules
• Cobamamide Capsules
• Cetirizine Hydrochloride Tablets
• Tofacitinib Citrate Tablets

The newly listed products cover various dosage forms, including injections, oral tablets, capsules, and dry suspensions, enabling them to meet diverse clinical needs and patient requirements.

As an established pharmaceutical manufacturer with extensive experience in the industry, Xinhua Pharmaceutical has continued to align its product development and manufacturing strategies with national healthcare policies and clinical needs. The company places strong emphasis on product quality, manufacturing capabilities, and supply chain management while continuously expanding and optimizing its product portfolio.

With the inclusion of these products in the 2026 National Essential Medicines List, Xinhua Pharmaceutical is expected to further leverage its manufacturing and supply chain capabilities to ensure stable production and supply, supporting the availability of essential medicines across different levels of healthcare institutions.

Looking ahead, Xinhua Pharmaceutical will continue to focus on clinical needs, strengthen pharmaceutical innovation and manufacturing capabilities, and expand its portfolio of high-quality medicines. Through continuous improvement of its industrial and supply chain capabilities, the company aims to contribute to the accessibility and stable supply of essential medicines and support the development of China’s national healthcare system.